

ABOUT AVITA MEDICAL LTD

Avita Medical develops and distributes regenerative products for the treatment of a broad range of wounds, scars and skin defects. Avita's patented and proprietary tissue-culture, collection and application technology provides innovative treatment solutions derived from a patient's own skin.

The Company's lead product, ReCell ™ Spray-On Skin™, is used in a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell is patented, CE-marked for Europe, TGA-registered in Australia, and SFDA-cleared in China. ReCell is not available for sale in the United States; in the US ReCell is an investigational device limited by federal law to investigational use. A Phase III FDA trial is in process.

www.avitamedical.com

BUSINESS OVERVIEW 2014

AVITA MEDICAL CONTINUED TO ADVANCE TRIALS, REIMBURSEMENT AND SALES OF OUR REGENERATIVE PRODUCT, RECELL® SPRAY-ON SKIN® THROUGHOUT THE 2014 FINANCIAL YEAR TO FURTHER THE DEVELOPMENT AND COMMERCIALISITION AVITA MEDICAL'S UNIQUE REGENERATIVE TECHNOLOGY.

In particular, the Company continued to pursue clinical trials in broader clinical applications of chronic wounds and aesthetics which have larger demand opportunities, while continuing ongoing efforts in the burns segment. In addition, the Avita's marketing effort was revamped to better monetise the ReCell technology in markets where ReCell has received regulatory approval.

The Company's Respiratory product line remained a significant generator of revenue, providing substantial funds to support the Regenerative (ReCell) business.

In a post financial year event, the Company's Board of Directors committed to increase investment in the Respiratory product line in order to stimulate additional revenue from the Respiratory business, while clinical and commercial acceptance and sales of ReCell continue to build.

Annual revenues from ReCell® Spray-On Skin® for the financial year were 5% higher than the previous financial year. Although sales growth was tracking considerably higher for the nine months to 31 March 2014 (up 21% compared to the prior corresponding period), management determined that as part of a transition to a commercialisation-focused organisation, an overhaul of the marketing and sales strategy and teams was prudent.

This undertaking prompted a short-term reduction in sales in the last quarter but is expected to yield improved results in the medium and long term.

Avita's renewed marketing effort will focus largely on chronic lower limb wounds and aesthetics (including repigmentation).

The commercialisation focus in specific clinical areas will target market awareness and education through development of improved messaging and branding. Further, improved cost analyses and health economic tools highlighting advantages of the use of ReCell will be made available to key stakeholder groups for incorporation into their business plans.

Together with development of complementary partnership initiatives with companies possessing relevant, existing sales channels, the net result is anticipated to be increased generation of sustainable, recurring sales. To support this strategy the ReCell platform technology is being developed into three brand identities and configurations, to specifically address the varied requirements and opportunities found across the Chronic Wounds, Aesthetics, and Burns indications.

This work builds on the early CY2014 development and release of a new version of ReCell that no longer requires refrigeration. The regulatory approval and commercial launch of the non-refrigerated ReCell is part of Avita's continuing effort to enhance the product's value proposition to the clinical market.

Successful trial results that demonstrate the clinical benefits of ReCell reinforce the commercialisation focus.

Most recently, a clinical study in Germany found ReCell provided clinically superior results for the treatment of hypopigmented scars. The ongoing study by German-based Associate Professor Dr Matthias Aust found that areas treated with ReCell combined with a scar treatment technique called medical needling showed statistically significant repigmentation, while the areas treated by medical needling without ReCell, did not.

In another trial, ReCell was used successfully in place of costly permanent laboratory facilities. which require special licensure, in the treatment of patients with vitiligo or piebaldism. The pilot study was a within-subject randomised controlled trial facilitated by the Netherlands Institute for Pigment Disorders. These important results have been accepted for presentation at the upcoming International Pigment Cell Conference (4-7 September) in Singapore. Avita is progressing discussions with the United States Food and Drug Administration (US FDA) to modify the US burns trial to resolve an ongoing issue with the strict criteria for patient participation which has been impacting recruitment.

The US FDA granted Avita an Investigational Device Exemption (IDE) for compassionate use of ReCell, allowing the Company to clinically evaluate the use of ReCell in up to 12 patients who have insufficient healthy skin to harvest for the skin grafts needed to conventionally treat their life-threatening wounds from burn, trauma, or congenital skin defects.

This clinical work is in alignment with the Company's effort toward re-focusing the positioning of ReCell in burns by highlighting the benefit to patients resulting from substantial reduction in the requirement for harvesting of patients' skin needed for conventional grafting treatment.

The addition of Cardiff University Hospital of Wales and Bradford Royal Infirmary, both in the UK, in Avita's multi-centre randomised control trial of ReCell for the treatment of venous leg ulcers, immediately improved patient participation. As a result, the Company is now nearly halfway to achieving its nominated 65 participants and on track to meet the Q1 CY2015 milestone for completion of enrolment.

Part of Avita's commercialisation strategy is to secure reimbursement listing to improve the attractiveness of ReCell for clinicians. Obtaining reimbursement is difficult in a healthcare environment that is cost-constrained worldwide; however, there is considerable potential benefit to Avita.

The Company continues to engage the UK
National Institute for Health and Care
Excellence (NICE) Medical Technologies
Advisory Committee to seek guidance along the
pathway towards a reimbursement listing.

CORPORATE

Lou Panaccio commenced as Chairman on July 1, 2014, replacing Ian Macpherson who fulfilled the role in an interim capacity since November 2013. Mr Macpherson remains on the Board in the role of Deputy Chairman.

FINANCIAL PERFORMANCE

Strong fiscal management and a program to reduce operational costs helped Avita record a 36% financial improvement in the year ended 30 June 2014, with a net loss after tax of \$5.1 million compared to \$8.1 million at 30 June 2013.

This was achieved despite a reduction in revenue from the Sale of Goods of \$2.7m, a decrease of 5% from the prior year of \$2.8 million. Total Revenues were \$3.3 million compared to \$4.1 million for the year ended 30 June 2013.

The decrease was largely due to an 8% drop in Respiratory sales compared to last year. In a post financial year event, the Board has resolved to invest in the marketing of the Company's Respiratory product line, Breath-a-Tec and Funhaler, so that it continues to provide an important revenue stream for the Company while ReCell is developed and commercialised.

Revenues for ReCell were 5% higher than FY2013. ReCell growth was achieved in Australia, China, France, and Turkey. In the UK, Germany, and Italy revenue declined primarily as a result of changes to staffing and sales representation. The Board expects that the marketing overhaul undertaken in the fourth quarter of the financial year will start to yield revenue growth in the first half of FY2015.

Other Income was 52% lower than last year, with Interest Received down 55% as cash deposits have steadily lowered. Grant income was also 56% lower than last year as Armed Forces Institute of Regenerative Medicine (AFIRM) funding came to an end during the year. Discussions with AFIRM and other potential US funding agencies are presently underway, in parallel with the US FDA burns trial negotiations, to progress new funding options.

Operating costs were \$9.2 million compared to \$11.6 million last year as a result of savings particularly in Research & Development (down 70% compared to last year).

FOR FURTHER INFORMATION:

Avita Medical Ltd. Lou Panaccio Chairman

Phone: +61 (0) 8 9474 7738

Avita Medical Ltd.
Tim Rooney

Interim Chief Executive Officer/Chief

Financial Officer

Phone: + 1 (818) 827-1695

Email: trooney@avitamedical.com





Appendix 4E

Preliminary Financial Report 30 June 2014

AVITA MEDICAL LIMITED

ABN 28 058 466 523

Results for announcement to the market

	Movement	June 2014	June 2013
Financial Results		\$	\$
Sale of goods	Down 5%	2,683,133	2,814,990
Other revenue	Down 52%	594,581	1,237,285
Total comprehensive loss for the period	Down 36%	5,111,902	7,959,436
Net Loss from ordinary activities after tax attributable to members	Down 36%	5,147,391	8,092,939

Dividends	Amount per Ordinary Security	Franked amount per security
2014 interim dividend	Nil	Nil
2013 interim dividend	Nil	Nil

i Record date for determining entitlements to interim dividends	Record date for determining ent	tlements to interim dividends	N/A	
-----------------------------------------------------------------	---------------------------------	-------------------------------	-----	--

Net Tangible Asset Backing	June 2014	June 2013
Net tangible asset backing per ordinary security	\$0.017	\$0.032

1



AVITA MEDICAL LIMITED STATEMENT OF COMPREHEHSIVE INCOME FOR THE YEAR ENDED 30 JUNE 2014

	Notes	Consol 2014	idated 2013
		2014 \$	2013 \$
Continuing operations		*	*
Sale of goods	2	2,683,133	2,814,990
Cost of sales	-	(670,893) 2,012,240	(676,502)
Gross profit		2,012,240	2,138,488
Other Revenue	2	594,581	1,237,285
Operating costs			
Administrative expenses		(5,639,513)	(5,449,632)
Share based payments		(183,214)	(82,338)
Research and development expenses		(784,113)	(2,601,046)
Sales and marketing expenses		(2,633,418)	(3,390,659)
Finance costs Amortisation of intellectual property		(25,675)	(91)
Amortisation of intellectual property	=	- // /E0 113\	(73,000)
Loss from continuing operations before income tax		(6,659,112)	(8,220,993)
Income tax benefit	<u>-</u>	1,511,721	128,054
Loss for the period		(5,147,391)	(8,092,939)
Other comprehensive income / (expense)			
Items that may be reclassified subsequently to profit and loss:			
Foreign currency translation	_	35,489	133,503
Other comprehensive (expense) / income for the period, net of tax		35,489	133,503
Total other comprehensive expense for the period	=	(5,111,902)	(7,959,436)
Loss for the period is attributable to:			
Non-controlling interest		_	-
Owners of Avita Medical Limited		(5,147,391)	(8,092,939)
	-	(5,147,391)	(8,092,939)
Other comprehensive expense for the period is attributable to:	=	(6):://67:/	(6/6/2//01/
Non-controlling interest		_	-
Owners of Avita Medical Limited		(5,111,902)	(7,959,436)
omios of the modera and	_	(5,111,902)	(7,959,436)
	-	(0,111,702)	(1,707,700)
Docinion was about attributable to audit and a suit to be suit to be a	2	(1 [0)	(2 (0)
Basic loss per share attributable to ordinary equity holders of the parent	3 3	(1.58) cents	(2.69) cents
Diluted loss per share attributable to ordinary equity holders of the parent	3	(1.58) cents	(2.69) cents



AVITA MEDICAL LIMITED STATEMENT OF FINANCIAL POSITION AS AT 30 JUNE 2014

2014	
2014 \$	2013 \$
ASSETS	<u> </u>
Current Assets	
	0,616,849
	1,215,382
Prepayments 195,473	187,586
Inventories 6 <u>782,236</u>	761,785
Total Current Assets 7,173,038 1	2,781,602
Non-Current Assets	
Plant & equipment 7 <u>139,801</u>	127,029
Total Non-Current Assets 139,801	127,029
TOTAL ASSETS 7,312,839 1	2,908,631
LIABILITIES	
Current Liabilities	
	2,243,783
Provisions 10 96,965	209,538
Total Current Liabilities 1,786,217	2,453,321
TOTAL LIABILITIES 1,786,217	2,453,321
NET ASSETS5,526,6221	0,455,310
EQUITY	
Equity attributable to equity holders of the parent	
	1,441,930
	1,706,766)
Reserves <u>686,861</u>	720,146
TOTAL EQUITY 5,526,622 1	0,455,310



AVITA MEDICAL LIMITED
PRELIMINARY FINAL REPORT
STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 30 JUNE 2014

	Consolidated	
	2014	2013
	\$	\$
Cash flows from operating activities		
Receipts from customers	2,925,693	2,990,444
Payments to suppliers and employees	(10,548,853)	(11,567,164)
Government grants received	343,278	787,578
Tax refund received	129,315	90,123
Interest received	186,002	412,354
Interest paid	(25,675)	(91)
Royalties and other income received	65,301	37,353
Net cash flows used in operating activities	(6,924,939)	(7,249,403)
Cash flows from investing activities Purchase of plant & equipment Gain on disposal of plant & equipment Net cash flows used in investing activities	(75,541) 5,000 (70,541)	(83,596) - (83,596)
Cash flows from financing activities		
Proceeds from issue of shares and options	-	10,401,081
Capital raising expenses		(673,650)
Net cash flows provided by (used in) financing activities		9,727,431
Net increase / (decrease) in cash and cash equivalents	(6,995,480)	2,394,432
Cash and cash equivalents at beginning of period	10,616,849	8,230,593
Impact of foreign exchange	27,021	(8,176)
Cash and cash equivalents at end of period	3,648,390	10,616,849



Consolidated	Contributed equity	Accumulated losses	Employee equity benefit reserve \$	Foreign currency translation reserve \$	Total \$	
At 1 July 2013 Loss for the period Other comprehensive income	111,441,930	(101,706,766) (5,147,391)	962,277 -	(242,131)	10,455,310 (5,147,391)	-
 Foreign currency translation Total comprehensive 		-	-	35,489	35,489	-
income for the year Transactions with		(5,147,391)	-	35,489	(5,111,902)	-
owners in their capacity as owners: Expired options Share based payments	- -	251,988 -	(251,988) 182,214	- -	- 182,214	
Balance at 30 June 2014	111,441,930	(106,602,169)	893,503	(206,642)	5,526,622	-
Consolidated	Contributed equity	Accumulated losses	Option premium reserve	Employee equity benefit reserve	Foreign currency translatio n reserve	Total
	\$	\$	\$	\$	\$	\$
At 1 July 2012 Loss for the period Other comprehensive income - Foreign currency	101,663,499	(96,676,634) (8,092,939)	2,277,759 -	1,664,987 -	(375,634) -	8,553,977 (8,092,939)
translation		-	-	-	133,503	133,503
Total comprehensive income for the year		(8,092,939)		-	133,503	(7,959,436)
Transactions with owners in their capacity as owners:		2.0/2.007	(2.277.750)	(705.040)		
Expired options New shares	10,452,080	3,062,807	(2,277,759)	(785,048)	-	- 10,452,080
Share based payments Costs of share	-	-	-	82,338	-	82,338
placements	(673,649)	-	-	-	-	(673,649)
Balance at 30 June 2013	111,441,930	(101,706,766)	-	962,277	(242,131)	10,455,310





BASIS OF PREPARATION AND ACCOUNTING POLICIES

Basis of Preparation

This general purpose condensed financial report for the year ended 30 June 2014 has been prepared in accordance Australian Accounting Standards (including Australian Accounting Interpretations) and other authoritative pronouncements of the Australian Accounting Standards Board, and the *Corporations Act 2001*.

This financial report does not include all notes of the type normally included within the annual financial report and therefore cannot be expected to provide as full an understanding of the financial performance, financial position and financing and investing activities of the consolidated entity as the full financial report.

It is recommended that this financial report be read in conjunction with any public announcements made by Avita Medical Limited during the year ended 30 June 2014 in accordance with the continuous disclosure obligations of the *ASX listing rules*.

The accounting policies and methods of computation are the same as those adopted in the most recent annual financial report.

Commentary on the results for the period

Revenue from the sale of goods, other revenue and other income was \$3,277,714, a decrease of 19% over last year (2013: 4,052,478). Revenue from sale of goods was \$2,683,133, down 5% over the previous year (2013: \$2,814,990). Cost of sales were \$670,893 (2013: \$676,502) up 8% due to manufacturing cost gains while gross profits at \$2,012,240 (2013: \$2,138,488) decreased by only 6%. Normal operating costs were \$9,265,933 (2013: \$11,596,766) a decrease of 20% compared to last year. This reflects management's initiative to reduce operating costs primarily in Research & Development expenditure (down 70%) compared to last year. The net loss before tax was \$6,659,112 down 19% on last year (2013: \$8,220,993).





2. REVENUES AND EXPENSES

Revenue and Expenses from Continuing Operations

		Consolida	nted
		2014	2013
(a)	Revenue	\$	\$
(a)	Sale of goods	2,683,133	2,814,990
(b)	Other revenue		
	Bank interest receivable	186,002	412,354
	Contracts received	343,278	787,578
	Other income	65,301	37,353
	Total Other Revenue	594,581	1,237,285
	Total Revenue	3,277,714	4,052,275
(c)	Finance costs Other loans	Consolida 2014 \$ 25,675	2013 \$
	_	25,675	91
(d)	Depreciation, impairment and amortization included in income statement	Consolida 2014 \$	ated 2013 \$
(u)	Depreciation, impairment and amortization included in income statement.	63,711	48,924
	Loss on disposal of plant & equipment	(3,656)	2,870
	Amortisation of intangible property	-	73,000
		Consolida	
		2014	2013
	_	\$	\$
(e)	Lease payments and other expenses included in income statement	170 505	170 505
	Minimum lease payments – operating lease	179,595	179,595



2. REVENUES AND EXPENSES (continued)

		Consolidated	
		2014	2013
		\$	\$
(f)	Employee benefits expense included in income statement		_
	Wages and salaries	3,003,424	3,239,424
	Defined contribution superannuation expense	241,418	163,838
	Share-based payments expense	183,214	82,338
		3,428,056	3,485,600

3. LOSS PER SHARE

Basic loss per share amounts are calculated by dividing the net loss for the year attributable to ordinary equity holders of the parent by the weighted average number of ordinary shares outstanding during the year.

Diluted earnings per share amounts are calculated by dividing the net loss for the year attributable to ordinary equity holders of the parent by the weighted average number of ordinary shares outstanding during the year plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares.

The following reflects the income and share data used in the basic and diluted loss per share computations:

	Consolidated	
	2014 \$	2013 \$
Net loss attributable to ordinary equity holders of the parent	(5,147,391)	(8,092,939)
Weighted average number of ordinary shares for basic loss per share	325,308,404	300,507,224

There have been no other transactions involving ordinary shares or potential ordinary shares between the reporting date and the date of completion of these financial statements.

4. CURRENT ASSETS - CASH AND CASH EQUIVALENTS

	Consolidated		
	2014 \$	2013 \$	
Cash at bank and in hand Short-term deposits	765,692 2,882,698	1,316,283 9,300,566	
	3,648,390	10,616,849	





5. CURRENT ASSETS - TRADE AND OTHER RECEIVABLES

o. Gorner Modero Marker Mark Regelvingers	Consolidated	
	2014 \$	2013 \$
Trade receivables Allowance for doubtful debts	507,020 (9,837)	947,406 (174,287)
Other receivables	497,123 2,049,756	773,119 442,263
Carrying amount of trade and other receivables	2,546,939	1,215,382

6. CURRENT ASSETS - INVENTORIES

	Consolidated		
	2014 \$	2013 \$	
Raw materials and components (at cost) Finished goods (at cost)	312,407 469,829	312,037 449,748	
Total inventories at cost	782,236	761,785	



7. NON-CURRENT ASSETS - PLANT & EQUIPMENT

(a) Reconciliation of carrying amounts at the beginning and end of the period

	Consolidated
	Plant and Equipment \$
Year ended 30 June 2014	
At 1 July 2013, net of accumulated depreciation	127,029
Exchange movements	3,468
Additions	75,541
Disposals	(2,526)
Depreciation charge for the year	(63,711)
At 30 June 2014, net of accumulated depreciation	139,801
At 30 June 2014	
Cost	740,405
Accumulated depreciation	(600,604)
Net carrying amount	139,801
	Consolidated
	Plant and Equipment \$
Year ended 30 June 2013	
At 1 July 2012, net of accumulated depreciation	87,051
Exchange movements	8,176
Additions	83,596
Disposals	(2,870)
Depreciation charge for the year	(48,924)
At 30 June 2013, net of accumulated depreciation	127,029
At 30 June 2013	
Cost	741,326
Accumulated depreciation	(614,297)
Net carrying amount	127,029



8. CURRENT LIABILITIES - TRADE AND OTHER PAYABLES

	Consolida	Consolidated		
	2014 \$	2013 \$		
Trade payables Accruals and other payables	440,936 1,248,316	971,719 1,272,064		
	1,689,252	2,243,783		

9. CURRENT LIABILITIES - PROVISIONS

\sim				
1.	ons	α	1ate	'n

	Employee benefits \$	Provision for annual leave	Provision for long service leave \$	Total
Current At 1 July 2013	30,242	150,231	29,065	209,538
Additional provisions Amount Utilised	(30,242)	(84,954)	2,623	(27,619) (84,954)
At 30 June 2014	-	65,277	31,688	96,965

AVITA MEDICAL LIMITED NOTES TO THE PRELIMINARY FINAL REPORT FOR THE YEAR ENDED 30 JUNE 2014



10. SEGMENT INFORMATION

The Group's chief operating decision maker has been identified as the Chief Executive Officer.

The Chief Executive Officer reviews the financial and operating performance of the business primarily from a geographic perspective. On this basis management have identified three reportable segments being:

- the Asia Pacific region;
- the Americas (including Canada); and
- the EMEA region (Europe, Middle East and Africa).

The Chief Executive Officer monitors the performance of all these segments separately. The Group does not operate in any other geographic segment. The Chief Executive Officer assesses the performance of the operating segments based on a measure of gross margin and net profit before tax.

Unallocated:

The following items of income and expense and associated assets are not allocated to operating segments as they are not considered part of the core operations of any segment:

- Corporate revenue
- Corporate charges
- Amortisation of intellectual property

The segment information provided to the Chief Executive Officer for the reportable segments for the year ended 30 June 2014 is as follows:

	Asia Pacific \$	EMEA \$	Americas \$	Total \$
Year ended 30 June 2014				
Revenue				
Sale of goods	2,188,489	494,644	-	2,683,133
Other revenues from external customers	53,507	1,677	353,395	408,579
Interest received	182,720	2,450	832	186,002
Total revenue and other income per consolidated statement of profit or				
loss and other comprehensive income	2,424,716	498,771	354,227	3,277,714
Segment net operating profit / (loss) before tax Reconciliation of segment net result before tax to loss before income tax:	332,909	(2,264,792)	(3,206,295)	(5,138,178)
Corporate charges				(1,520,934)
Loss before income tax				(6,659,112)
	Continuing Operations Asia Pacific EMEA Americas \$ \$ \$		Americas	Total \$
Year ended 30 June 2014				
Segment assets	2 / 05 075	1 005 070	1 054 700	4/0///2
Segment operating assets Unallocated assets	2,605,975	1,025,979	1,054,709	4,686,663 2,626,176
Total Assets per the statement of				2,626,176
financial position			_	7,312,839



AVITA MEDICAL LIMITED NOTES TO THE PRELIMINARY FINAL REPORT FOR THE YEAR ENDED 30 JUNE 2014

10. SEGMENT INFORMATION (continued)

	Continuing Operations			
	Asia Pacific	EMEA ¢	Americas _#	Total
Year ended 30 June 2013	<i>\$</i>	<i>\$</i>	<i>\$</i>	\$
Revenue				
Sales to external customers	2,256,248	550,647	8,095	2,814,990
Other revenues from external customers	100,604	13	724,314	824,931
Interest received	410,249	1,163	942	412,354
Total revenue per statement of		,		
comprehensive income	2,767,101	551,823	733,351	4,052,275
Segment net profit / (loss) before tax	527,063	(2,744,469)	(4,392,849)	(6,610,483)
Reconciliation of segment net result		(=,:::,:::,	(1,01=,011)	(2,2.2,12.2)
before tax to loss before income tax				
Corporate charges				(1,537,510)
Amortisation of intellectual property				(73,000)
Loss before income tax per statement of comprehensive income				(8,220,993)
or comprehensive income				(0,220,773)
	Continuing Operations			
	Asia Pacific	EMEA	Americas	Total
V 1 100 1 0010	\$	<i>\$</i>	\$	\$
Year ended 30 June 2013				
Segment assets Segment operating assets	1,145,385	1,800,391	1,313,781	4,259,557
Unallocated assets	1,140,300	1,000,391	1,313,701	4,259,557 8,649,074
Total Assets per the statement of				0,047,074
financial position				12,908,631

There was no material difference between the basis of segmentation and the measurement of segment result as compared to that in the 30 June 2013 annual report.





11. CONTRIBUTED EQUITY

	CONSOLIDATED		
	2014	2013	
	\$	\$	
Ordinary shares			
Issued and fully paid	111,441,930	111,441,930	
	111,441,930	111,441,930	
Movement in ordinary shares on issue	Number of shares	\$	
At 1 July 2013	325,308,404	111,441,930	
Shares issued	-	-	
Capital issue costs	_	-	
At 30 June 2014	325,308,404	111,441,930	

12. RELATED PARTY DISCLOSURES

The total amount of transactions entered into with key management personnel for the year ended 30 June 2014 are as follows:

- (i) During the period fees of \$43,000 (2013: \$nil) were paid, under normal terms and conditions, to the F.A.T.S Pty Ltd of which I Macpherson is a director.
- (ii) During the period fees of \$45,646 (2013: \$90,030) were paid, under normal terms and conditions, to Gooding Partners Chartered Accountants, of which D Gooding is a partner.

13. COMMITMENTS AND CONTINGENCIES

There are no commitments and contingencies which require disclosure in this report.

14. EVENTS SUBSEQUENT TO BALANCE DATE

No subsequent events have occurred since the Balance Sheet Date which require disclosure in this report.



Annual meeting

	The annual me	eeting will be held as follows:				
	Place		TBA			
	Date		Provisionally set as 21 November 2014			
	Time		2pm (EST)			
	Approximate of	date the +annual report will be available	1 October 2014			
Comp	oliance staten	nent				
1	This report ha	s been prepared in accordance with AA	ASB Standards, other AASB authoritative pronouncements at	nd		
2	This report, an	d the +accounts upon which the report is	based (if separate), use the same accounting policies.			
3	This report doe	es give a true and fair view of the matters	s disclosed			
4	This report is t	This report is based on †accounts to which one of the following applies.				
		The $^{+}$ accounts have been \square audited.	The †accounts have been subject to review.			
	✓	The ⁺accounts are in the □ process of being audited or subject to review.	The +accounts have <i>not</i> yet been audited or reviewed.			
5	The entity has a formally constituted audit committee.					
Sign he	ere:					
Date:	28 August 2014	1				
	el Chiappini Pany Secretary	,				